[2]. Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P; PERFORM and SPARCL Investigators and Committees. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 2014;45:1429–1436.

[3]. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Armitage CR. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–212.

[4]. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255–2267。

[5]. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima JAC, Puri R, Nomura SO, Tsai MY, Wilkins JT, Ballantyne CM, Nicholls SJ, Jones SR, Elshazly MB. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021 Jul 19:ehab432.

[6]. Olga Castañer, Xavier Pintó, Isaac Subirana, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With IncidentCardiovascular Disease. J Am Coll Cardiol. 2020;76（23）:2712–2724.

[7]. John R. Burnett, Amanda J. Hooper, Robert A. Hegele. Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2020;76（23）:2736–2739.

[8]. Hae Won Jung, Seung-Pyo Hong*, Kee-Sik Kim. Comparison of apolipoprotein B/A1 ratio, TC/HDL-C, and lipoprotein （a） for predicting outcomes after PCI. PLoS ONE 16（7）: e0254677.

本文首发：医学界心血管频道

本文作者：孙铁男

责任编辑：詹雨 刘凤玲

版权申明

本文原创，转载需联系授权

- End -

投稿/转载/商务合作，请联系：yxjxxg@yxj.org.cn

来源：医学界心血管频道

本文仅代表作者个人观点，与本网无关。